Researchers at Keck Medicine, University of Southern California (USC) have discovered that combining immunotherapy with laser heat therapy could significantly extend the survival of individuals diagnosed with deadly brain cancers. This breakthrough offers new hope for patients with glioblastoma and other aggressive brain tumors, which have historically had poor prognoses.
The study, conducted by a team of scientists at USC, involved using laser interstitial thermal therapy (LITT) to heat and destroy tumor cells, followed by immunotherapy to boost the body's immune response against any remaining cancer cells. The combination therapy was found to dramatically improve survival rates in preclinical models, paving the way for clinical trials in humans.
According to the researchers, the laser treatment not only kills cancer cells but also releases tumor antigens that can be recognized by the immune system. By then administering immunotherapy, the immune system is primed to attack the tumor more effectively. This dual approach addresses the challenge of brain tumors being able to evade immune detection.
The implications of this research are significant, as brain tumors like glioblastoma are notoriously difficult to treat. Standard treatments, including surgery, radiation, and chemotherapy, often have limited success, and the average survival time for patients is just 15 months. The new combination therapy could potentially double or triple that survival time.
Entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are actively engaged in developing novel treatments for brain cancers, and this research could influence future drug development and treatment protocols.
The findings were published in a peer-reviewed journal and have garnered attention from the medical community. Experts caution that while the results are promising, further studies are needed to confirm the efficacy and safety in human patients. Clinical trials are expected to begin within the next year.
This research was supported by grants from the National Institutes of Health and other organizations. For more information about the study, visit the Keck Medicine website.
